Clinical Trial Update: Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial sponsored by UCLA is evaluating fimepinostat, a dual HDAC and PI3-kinase inhibitor, for Cushing disease and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Disease

Drugs mentioned

• Fimepinostat (fimepinostat)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Cushing Disease | Phase 2 | Status: RECRUITING